^
Association details:
| Biomarker: | IGH mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Excerpt:
Recommendations: CLL with mutated-IGHV status and without TP53 mutation or del(17p) (if there was similar efficacy, panel is giving preference to time-limited therapies)...venetoclax plus obinutuzumab [I, A] or chlorambucil plus obinutuzumab or ibrutinib or acalabrutinib [I, A].
Secondary therapy:
chlorambucil
DOI:
10.1016/j.annonc.2020.09.019
Source:
Title:
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Excerpt:
Recommendations: CLL with mutated-IGHV status and without TP53 mutation or del(17p) (if there was similar efficacy, panel is giving preference to time-limited therapies)...CIT according to age (FCR or BR) or ibrutinib [I, A]. Venetoclax plus obinutuzumab might be an alternative to BTKis...
DOI:
10.1016/j.annonc.2020.09.019
Source:
Title:
FIXED-DURATION IBRUTINIB AND VENETOCLAX (I+V) VERSUS CHLORAMBUCIL PLUS OBINUTUZUMAB (CLB+O) FOR FIRST-LINE (1L) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRIMARY ANALYSIS OF THE PHASE 3 GLOW STUDY
Published date:
05/12/2021
Excerpt:
Pts were randomized 1:1, stratified by IGHV mutation and del(11q) status, to I+V (3 cycles ibrutinib 420 mg/d, followed by 12 cycles I+V with venetoclax...At 3 mo after end of treatment (EOT+3), rate of uMRD was significantly higher for I+V vs Clb+O in BM (51.9% vs 17.1%; p < 0.0001) and peripheral blood (PB; 54.7% vs 39.0%; p = 0.0259).
Secondary therapy:
venetoclax
Trial ID:
